The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.
I
n 2019, the American Diabetes Association (ADA) added a new section on diabetes technology to the Standards of Medical Care in Diabetes. Diabetes technology is the devices, hardware, and software that persons with diabetes use to help manage blood glucose levels. Such technology includes pens or pumps that administer insulin and meters or continuous glucose monitors that measure blood glucose. Recent evolutions addressed in this synopsis are devices that both monitor glucose and deliver insulin, and software that serves as a medical device by supporting diabetes self-management.
GUIDELINE DEVELOPMENT AND EVIDENCE GRADING
The Professional Practice Committee of the ADA is an expert committee comprising physicians, diabetes educators, and others who have expertise in such areas as adult and pediatric endocrinology, public health, epidemiology, lipids and hypertension, pregnancy care, and preconception planning. Appointment to the Committee is based on excellence in research or clinical care. For the current revision, members systematically searched MEDLINE through November 2018 for studies that were related to each section and had been published since 15 October 2017. Recommendations were revised to incorporate new evidence, clarify the prior recommendation, or align the strength of the wording to that of the evidence. The standards were approved by the ADA's Board of Directors, which consists of health care professionals, scientists, and laypersons.
The recommendations are rated as A, B, C, or E. Those with an A rating are based on large, welldesigned clinical trials or high-quality meta-analyses. Recommendations with lower-quality evidence may also be important and are based on well-conducted cohort studies (B rating) or uncontrolled studies (C rating). Recommendations are assigned an E rating when there is no evidence from clinical trials, clinical trials might be impractical, or evidence is conflicting.
The ADA funds development of the standards from its general revenues, with no industry involvement or support. Details on the methods, information about the committee members and their conflict-of-interest disclosures, and the complete standards can be downloaded at https://professional.diabetes.org/annals.
SELF-MONITORING OF BLOOD GLUCOSE

Recommendations
Most patients using intensive insulin regimens (multiple daily injections or insulin pump therapy) should assess glucose levels using self-monitoring of blood glucose (SMBG) Self-monitoring of blood glucose-a technology used in the major clinical trials of patients who receive insulin-is an integral part of therapy for such patients (1) . Continuous glucose monitoring is an additional method that gives continuous readings of glucose levels, allowing patients to see how medications, meals, and exercise affect blood glucose. It provides complementary information to that obtained with SMBG. Both SMBG and CGM help show patients their individual responses to therapy, and the results must be integrated into the diabetes management program to be useful in adjusting medications, guiding nutrition and exercise recommendations, and preventing hypoglycemia. 
Optimizing SMBG and Continuous Glucose Monitor Use
Patients' monitoring technique should be evaluated initially and at regular intervals. Optimal use of SMBG and CGM requires review and interpretation of data by both the patient and the provider. In patients with type 1 diabetes, more frequent use of these technologies has been associated with lower levels of hemoglobin A 1c (HbA 1c ) (2, 3) . However, many patients who report checking their blood glucose at least once daily also report taking no action when results are high or low (4). Patients should be taught how to use SMBG or CGM data to adjust food intake, exercise, and pharmacologic therapy. The need for and frequency of SMBG should be reevaluated at each visit to avoid overuse, particularly if SMBG is not being used effectively for self-management (4 -6).
For Patients Using Intensive Insulin Regimens
Use of SMBG or CGM is most important for insulintreated patients because it enables them to adjust therapy to minimize hypoglycemia and manage hyperglycemia. An observational study of almost 27 000 children and adolescents with type 1 diabetes showed that increased daily frequency of SMBG was significantly associated with lower HbA 1c levels (difference, Ϫ0.2 percentage points per additional test/d) and fewer acute complications (7).
For Patients Using Basal Insulin or Oral Agents
Evidence is insufficient to guide when to prescribe and how often to test SMBG for insulin-treated patients who are not using intensive insulin regimens. However, when fasting glucose monitoring is used to determine dose adjustments in patients using basal insulin, it results in lower HbA 1c levels (8, 9).
In patients with type 2 diabetes who are not using insulin, potential benefits of glucose monitoring include insight into the effects of diet, physical activity, and medication management. In addition, SMBG is useful in assessing hypoglycemia, glucose levels during intercurrent illness, and discrepancies between measured HbA 1c and glucose levels. Randomized trials, however, have raised questions about the clinical utility and cost-effectiveness of routine SMBG in non-insulintreated patients (10 -13). Reductions in HbA 1c levels were greater (change, Ϫ0.3 percentage points) in trials where structured SMBG data were used to adjust medications than in trials without such adjustment, where changes were not significant (14) . In addition, SMBG does not itself lower blood glucose levels; rather, its utility depends on the way in which the information is used and integrated into the patient's diabetes management plan.
Glucose Meter Accuracy
Recommendation
Health care providers should be aware of medications and other factors that can interfere with glucose meter accuracy and choose appropriate devices for their patients on the basis of these factors. (Grade E recommendation)
The U.S. Food and Drug Administration (FDA) uses the following accuracy standard for glucose monitors intended for home use: 95% of readings need to be within 15% for all blood glucose results in the monitor's readable range, and 99% must be within 20% (15, 16) . Accuracy varies among widely used systems for blood glucose monitoring. A recent study found that only 6 of the top 18 glucose meters met the defined accuracy standard (17) . Detailed information on individual devices can be found at the Diabetes Technology Society Blood Glucose Monitoring System Surveillance Program Web site (www.diabetestechnology.org/surveillance.shtml).
Factors Limiting Accuracy
Glucose monitors use either glucose oxidase or glucose dehydrogenase in the reaction to determine glucose levels (18) . Because glucose oxidase monitors depend on oxygen levels, these devices should be used only in patients whose oxygen saturation is normal. Higher oxygen tension (for example, from arterial blood readings or during oxygen therapy) can lead to falsely low glucose readings, and low oxygen tension (for example, at high altitude, during hypoxia, or from venous blood readings) can lead to falsely high readings. Glucose dehydrogenase monitors are not oxygendependent. Patients and physicians should also be aware of and avoid using counterfeit strips that have not been subject to quality control procedures because they may give inaccurate results.
CONTINUOUS GLUCOSE MONITORS Recommendations
Sensor Continuous glucose monitoring measures interstitial glucose (which correlates well with plasma glucose) through a small subcutaneous sensor. Devices are available as real-time devices that continuously report glucose levels and include alarms for both hyperglycemic and hypoglycemic excursions and intermittently scanned CGM (isCGM) devices, which are approved for adult use only. The latter devices (discussed in more detail under Use of Intermittently Scanned Continuous Glucose Monitors) neither communicate continuously nor provide real-time alarms, but they are less expensive than CGM systems with automated alerts. Although SMBG is required to make treatment decisions CLINICAL GUIDELINE Review of the 2019 ADA Standards of Medical Care in Diabetes with some CGM systems, the FDA has approved 2 CGM systems (Dexcom G5 and Dexcom G6) for decision making without a confirmatory SMBG check (19, 20) .
Systems for CGM provide a significant amount of patient data that can be incorporated into clinical practice and can lead to better treatment decisions (21 (25) and 0.6 percentage points (26). In the Juvenile Diabetes Research Foundation CGM study, a significant reduction of 0.53 percentage points was seen in a subset of adults primarily using continuous subcutaneous insulin infusion (2) . Consistent CGM use seems to be an important factor in reduction of HbA 1c levels (2, 34) .
In 1 study of 158 adults with type 2 diabetes mellitus using multiple daily insulin injections alone, CGM use reduced HbA 1c by an average of 0.3 percentage points (33) . A study in persons using oral agents with or without insulin (27) and another in patients using either multiple daily injections or continuous subcutaneous insulin infusion (28) showed significant reductions in HbA 1c levels.
Primary Outcome: Hypoglycemia
Use of CGM reduced hypoglycemia in adults with type 1 diabetes using multiple daily injections or continuous subcutaneous insulin infusion (29 -31) . In a study of patients with high risk for hypoglycemia (32) , CGM use reduced time in all levels of hypoglycemia. In adults with type 2 diabetes using oral medications with or without insulin, CGM did not reduce hypoglycemia rates (27, 28, 33) . It may be most useful in insulindependent patients with hypoglycemic unawareness or those with frequent hypoglycemic episodes. Findings conflict regarding reduction in severe hypoglycemia (2, 32, 35) .
Sensor-augmented pumps-an FDA-approved technology-suspend basal insulin when glucose is currently low or predicted to decrease below 3.89 mmol/L (70 mg/dL) in the next 30 minutes. The low-glucose suspend function reduced hypoglycemia over a 3-month period without raising HbA 1c levels in the ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study of 247 persons with type 1 diabetes and known nocturnal hypoglycemia (34) . In another study, predictive low-glucose suspend decreased time spent with HbA 1c levels below 3.89 mmol/L (70 mg/dL) from 3.6% to 2.6% (3.2% in the control group) over 6 weeks without leading to rebound hyperglycemia (36) .
Use of Intermittently Scanned Continuous Glucose Monitors: Recommendation Use of an intermittently scanned continuous glucose monitor can be considered as a substitute for SMBG in adults with diabetes requiring frequent glucose testing. (Grade C recommendation)
In 2017, the FDA-approved isCGM (sometimes called "flash" CGM) for use in adults. The personal version of isCGM has a receiver that displays real-time glucose values with trend arrows when the patient scans it over the sensor. Data can be uploaded and reports created using software either at home or in the provider's office. In the professional version, data are blinded to the patient because he or she does not carry a receiver while wearing the sensor and are then downloaded in the provider's office. The sensor, which requires only a 1-hour start-up time, can be worn for up to 14 days. The isCGM device comes factory calibrated and does not require calibration with SMBG. Accuracy of isCGM is not affected by acetaminophen. The sensor measures glucose levels every minute, records a measurement Review of the 2019 ADA Standards of Medical Care in Diabetes CLINICAL GUIDELINE every 15 minutes, and can display up to 8 hours of data on the receiver. Unlike real-time CGM systems, isCGM provides no blood glucose alerts, but its direct costs are lower than those of real-time CGM. Both the consumer and professional versions are covered by most commercial insurance carriers and eligible Medicare programs.
Studies in adults show that isCGM has excellent accuracy compared with SMBG (37-39). However, accuracy is lower at high and low glucose levels (21, 40) . Outcomes conflict regarding the accuracy of isCGM versus real-time CGM (40 -42) . In patients with type 1 (29) and type 2 (43) diabetes, isCGM may decrease hypoglycemia risk. Recent studies show both excellent performance and potential for benefit in several special populations of patients with diabetes, including pregnant women with diabetes (44) and persons with type 1 diabetes and hypoglycemia unawareness (45) .
Several thorough reviews have studied isCGM (46 -48). In 2017, the Norwegian Institute of Public Health reviewed isCGM and its clinical effectiveness, safety, and cost-effectiveness in persons with type 1 and type 2 diabetes (46). The authors reported that few quality data were available at the time of the report but that isCGM may increase time in range, reduce frequency of nocturnal hypoglycemia, and improve treatment satisfaction. In 2016, the Canadian Agency for Drugs and Technologies in Health reviewed isCGM's performance, accuracy, effect on HbA 1c levels and hypoglycemia, and patient satisfaction and quality of life and concluded that isCGM could replace SMBG in patients who require frequent SMBG testing (47) .
AUTOMATED INSULIN DELIVERY Recommendation
Automated insulin delivery systems can be considered in children (aged >7 years) and adults with type 1 diabetes to improve glycemic control. (Grade B recommendation)
Automated insulin delivery systems consist of an insulin pump, a continuous glucose sensor, and an algorithm that determines insulin delivery. These systems suspend, increase, or decrease insulin delivery on the basis of sensor glucose values. Recent studies suggest that these systems may have psychosocial benefits (25, 49 -51) and may reduce exercise-induced hypoglycemia (26).
A 3-month, noncontrolled trial involving 124 patients aged 14 to 75 years with type 1 diabetes and regular in-home use of insulin found that a firstgeneration, hybrid, closed-loop system (in which the user must calculate a bolus dose for carbohydrates) showed safety (52) and improved HbA 1c levels in adolescents (from 7.7% [SD, 0.8] to 7.1% [SD, 0.6]; n = 30) and adult users (from 7.3% [SD, 0.9] to 6.8% [SD, 0.6]; n = 94) (53) .
Future Systems
Many other automated systems for insulin delivery are under investigation, including those that use dual hormones (insulin plus glucagon or pramlintide). Some patients are choosing to create and build their own pancreas device systems out of FDA-approved devices using training modules from online communities. These systems do not have FDA approval, and the FDA recently warned of the risks of using unapproved or unauthorized devices for diabetes management (including CGM systems, insulin pumps, and automated insulin dosing systems) in the United States (54 -58 
